The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease

Neurobiology of Disease

Volumn 39, Issue 1, 2010, Pages 28-39

  Buckley, Noel J ^a   Johnson, Rory ^b   Zuccato, Chiara ^c   Bithell, Angela ^a   Cattaneo, Elena ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarker; Brain derived neurotrophic factor (BDNF); Chromatin; Chromatin immunoprecipitation; Dominant negative REST, RNAi; Epigenetic; Histone; Histone acetylation; Histone deacetylase; Histone methylation; Hungtingtin; Huntington's disease; Long non coding BNAs; Microarray; MicroRNAs; Post transcriptional; RE1 silencing transcription factor (REST); Synthetic peptide nucleic acid; Transcription

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MICRORNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REST; UNCLASSIFIED DRUG;

CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HUMANS; HUNTINGTON DISEASE; REPRESSOR PROTEINS; RNA INTERFERENCE;

EID: 77952888250     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.02.003     Document Type: Review

References (179)

1. Abel T., Zukin R. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
2. Abelson J.F., et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005, 310:317-320.
3. Aid T., et al. Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 2007, 85:525-535.
4. Altar C.A., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
5. Arzberger T., et al. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 1997, 56:440-454.
6. Augood S.J., et al. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 1996, 72:1023-1036.
7. Augood S.J., et al. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 1997, 42:215-221.
8. Bae B.I., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47:29-41.
9. Bak M., et al. MicroRNA expression in the adult mouse central nervous system. Rna 2008, 14:432-444.
10. Ballas N., et al. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005, 121:645-657.
11. Baquet Z.C., et al. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004, 24:4250-4258.
12. Barski A., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
13. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2003, 116:281-297.
14. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
15. Battaglioli E., et al. REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem. 2002, 277:41038-41045.
16. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 2004, 5:373-384.
17. Belyaev N.D., et al. Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes. J. Biol. Chem. 2004, 279:556-561.
18. Bird A. Perceptions in epigenetics. Nature 2007, 447:396-398.
19. Borovecki F., et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11023-11028.
20. Bothwell M., Giniger E. Alzheimer's disease: neurodevelopment converges with neurodegeneration. Cell 2000, 102:271-273.
21. Boutell J.M., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 1999, 8:1647-1655.
22. Bruce A.W., et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10458-10463.
23. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7:784-796.
24. Canzonetta C., et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am. J. Hum. Genet. 2008, 83:388-400.
25. Cavaille J., et al. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14311-14316.
26. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23:387-392.
27. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 2007, 83:228-248.
28. Cha J.H., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6480-6485.
29. Cha J.H., et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:981-989.
30. Chan J.A., et al. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
31. Chen Z.F., et al. NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis. Nat. Genet. 1998, 20:136-142.
32. Chong J.A., et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995, 80:949-957.
33. Chou S.Y., et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci. 2008, 28:3277-3290.
34. Conaco C., et al. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2422-2427.
35. Cramer P., et al. Functional association between promoter structure and transcript alternative splicing. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11459-11460.
36. Crocker S.F., et al. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res. 2006, 1088:176-186.
37. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
38. Deutsch S.I., et al. Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time?. Clin. Neuropharmacol. 2008, 31:104-119.
39. Diekmann H., et al. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009, 29:1343-1349.
40. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
41. Dinger M.E., et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008, 18:1433-1445.
42. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
43. Faghihi M.A., et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 2008, 14:723-730.
44. Fang H., et al. Cationic shell-cross-linked knedel-like (cSCK) nanoparticles for highly efficient PNA delivery. Mol. Pharm. 2009, 6:615-626.
45. Feng Z., et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 2006, 25:1-7.
46. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
47. Ferrante R.J., et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 2004, 24:10335-10342.
48. Furuno M., et al. Clusters of internally primed transcripts reveal novel long noncoding RNAs. PLoS Genet. 2006, 2:e37.
49. Futter M., et al. Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J. Med. Genet. 2009, 46:438-446.
50. Gardian G., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
51. Glozak M.A., et al. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
52. Greenway D.J., et al. RE1 silencing transcription factor maintains a repressive chromatin environment in embryonic hippocampal neural stem cells. Stem Cells 2007, 25:354-363.
53. Grimes J.A., et al. The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. J. Biol. Chem. 2000, 275:9461-9467.
54. Gutekunst C.A., et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8710-8714.
55. Guttman M., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458:223-227.
56. Hakimi M.A., et al. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7420-7425.
57. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 2003, 28:425-433.
58. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. HDCR.
59. Hebert C.G., et al. Beyond silencing-engineering applications of RNA interference and antisense technology for altering cellular phenotype. Curr. Opin. Biotechnol. 2008, 19:500-505.
60. Henley S.M., et al. Biomarkers for neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18:698-705.
61. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
62. Hodges A., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
63. Hodges A., et al. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav. 2008, 7:288-299.
64. Huang C.C., et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol. Genet. 1998, 24:217-233.
65. Huang Y., et al. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 1999, 2:867-872.
66. Humphrey G.W., et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 2001, 276:6817-6824.
67. Imarisio S., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412:191-209.
68. Iwata A., et al. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005, 280:40282-40292.
69. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
70. Jiang L., et al. Yin yang 1 directly regulates the transcription of RE-1 silencing transcription factor. J. Neurosci. Res. 2008, 86:1209-1216.
71. Johnson R., Buckley N.J. Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromolecular. Med. 2009, 11:183-199.
72. Johnson R., et al. Identification of the REST regulon reveals extensive transposable element-mediated binding site duplication. Nucleic Acids Res. 2006, 34:3862-3877.
73. Johnson D.S., et al. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007, 316:1497-1502.
74. Johnson R., et al. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 2008, 29:438-445.
75. Johnson R., et al. Regulation of neural macroRNAs by the transcriptional repressor REST. RNA 2009, 15:85-96.
76. Johnson R., et al. REST regulates distinct transcriptional networks in embryonic and neuronal stem cells. PLoS Biol. 2008, 6:e256.
77. Karres J.S., et al. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell 2007, 131:136-145.
78. Kawaguchi Y., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
79. Kazantsev A.G., Hersch S.M. Drug targeting of dysregulated transcription in Huntington's disease. Prog. Neurobiol. 2007, 83:249-259.
80. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
81. Kegel K.B., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 2002, 277:7466-7476.
82. Kim J., et al. A microRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
83. Kim M.O., et al. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J. Neurosci. 2008, 28:3947-3957.
84. Klein M.E., et al. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat. Neurosci. 2007, 10:1513-1514.
85. Kosik K.S. The neuronal microRNA system. Nat. Rev. Neurosci. 2006, 7:911-920.
86. Kosik K.S. The neuronal microRNA system. Nat. Rev. Neurosci. 2006, 7:911-920.
87. Krichevsky A.M., et al. A microRNA array reveals extensive regulation of microRNAs during brain development. Rna 2003, 9:1274-1281.
88. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 2002, 25:409-432.
89. Li S.H., et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol. 2002, 22:1277-1287.
90. Li X., et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 28:91-106.
91. Lim L.P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
92. Lipovich L., King M.C. Abundant novel transcriptional units and unconventional gene pairs on human chromosome 22. Genome Res. 2006, 16:45-54.
93. Lipovich L., et al. Primate-specific endogenous cis-antisense transcription in the human 5q31 protocadherin gene cluster. J. Mol. Evol. 2006, 62:73-88.
94. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
95. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
96. Lunyak V.V., et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 2002, 298:1747-1752.
97. Luthi-Carter R., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
98. Luthi-Carter R., et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11:1911-1926.
99. Makeyev E.V., et al. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 2007, 27:435-448.
100. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2:679-689.
101. Marullo M., et al. Analysis of the repressor Element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease. Brain Pathol. 2008.
102. Mattick J.S. RNA regulation: a new genetics?. Nat. Rev. Genet. 2004, 5:316-323.
103. Mehler M.F. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog. Neurobiol. 2008, 86:305-341.
104. Mehler M.F. Epigenetics and the nervous system. Ann. Neurol. 2008, 64:602-617.
105. Mehler M.F., Mattick J.S. Non-coding RNAs in the nervous system. J. Physiol. 2006, 575:333-341.
106. Meister G., et al. Identification of novel argonaute-associated proteins. Curr. Biol. 2005, 15:2149-2155.
107. Mortazavi A., et al. Comparative genomics modeling of the NRSF/REST repressor network: from single conserved sites to genome-wide repertoire. Genome Res. 2006, 16:1208-1221.
108. Naruse Y., et al. Neural restrictive silencer factor recruits mSin3 and histone deacetylase complex to repress neuron specific target genes. Proc. Natl. Acad. Sci. U. U. S. A. 1999, 96:13691-13696.
109. Nishihara S., et al. The canonical Wnt pathway directly regulates NRSF/REST expression in chick spinal cord. Biochem. Biophys. Res. Commun. 2003, 311:55-63.
110. Norris P.J., et al. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996, 72:1037-1047.
111. Nucifora F.C., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
112. Oliveira J.M., Goncalves J. In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J. Biol. Chem. 2009, 284:5010-5020.
113. Ooi L., Wood I.C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 2007, 8:544-554.
114. Ooi L., et al. BRG1 chromatin remodeling activity is required for efficient chromatin binding by repressor element 1-silencing transcription factor (REST) and facilitates REST-mediated repression. J. Biol. Chem. 2006, 281:38974-38980.
115. Otto S.J., et al. A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J. Neurosci. 2007, 27:6729-6739.
116. Packer A.N., et al. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 2008, 28:14341-14346.
117. Pandey U.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
118. Patel N., et al. MicroRNAs can regulate human APP levels. Mol. Neurodegener. 2008, 3:10.
119. Paulsen J.S., et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001, 57:658-662.
120. Perkins D.O., et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007, 8:R27.
121. Ponjavic J., Ponting C.P. The long and the short of RNA maps. Bioessays 2007, 29:1077-1080.
122. Pruunsild P., et al. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90:397-406.
123. Qureshi I.A., Mehler M.F. Regulation of non-coding RNA networks in the nervous system-what's the REST of the story?. Neurosci. Lett. 2009, 466:73-80.
124. Rando O.J., Verstrepen K.J. Timescales of genetic and epigenetic inheritance. Cell 2007, 128:655-668.
125. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007, 447:425-432.
126. Reiner A., et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5733-5737.
127. Rigamonti D., et al. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J. Biol. Chem. 2007, 282:24554-24562.
128. Rogelj B., et al. Contextual fear conditioning regulates the expression of brain-specific small nucleolar RNAs in hippocampus. Eur. J. Neurosci. 2003, 18:3089-3096.
129. Roopra A., et al. Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol. Cell Biol. 2000, 20:2147-2157.
130. Roopra A., et al. Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol. Cell 2004, 14:727-738.
131. Rosas H.D., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
132. Rosas H.D., et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
133. Rosas H.D., et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
134. Runne H., et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14424-14429.
135. Ryan A.B., et al. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis. Neurobiol. Dis. 2006, 24:419-427.
136. Ryu J.K., et al. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp. Neurol. 2004, 187:150-159.
137. Ryu H., et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19176-19181.
138. Sadri-Vakili G., et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 2007, 16:1293-1306.
139. Savas J.N., et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10820-10825.
140. Schaefer A., et al. Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 2007, 204:1553-1558.
141. Schoenherr C.J., Anderson D.J. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995, 267:1360-1363.
142. Schratt G.M., et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006, 439:283-289.
143. Selbach M., et al. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
144. Sempere L.F., et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004, 5:R13.
145. Shi Y., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
146. Shimojo M., Hersh L.B. Characterization of the REST/NRSF-interacting LIM domain protein (RILP): localization and interaction with REST/NRSF. J. Neurochem. 2006, 96:1130-1138.
147. Shin J.Y., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
148. Sipione S., et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 2002, 11:1953-1965.
149. Smirnova L., et al. Regulation of miRNA expression during neural cell specification. Eur. J. Neurosci. 2005, 21:1469-1477.
150. Stack E.C., et al. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
151. Stark K.L., et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat. Genet. 2008, 40:751-760.
152. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
153. Steffan J.S., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6763-6768.
154. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
155. Tachibana M., et al. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 2001, 276:25309-25317.
156. Tahiliani M., et al. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 2007, 447:601-605.
157. Thomas E.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15564-15569.
158. Timmusk T., et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 1993, 10:475-489.
159. Timmusk T., et al. Developmental regulation of brain-derived neurotrophic factor messenger RNAs transcribed from different promoters in the rat brain. Neuroscience 1994, 60:287-291.
160. Valenza M., et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 2005, 25:9932-9939.
161. Visvanathan J., et al. The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev. 2007, 21:744-749.
162. Vo N., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16426-16431.
163. Waddington C.H. The epigenotype. Endeavour 1942, 1:18-20.
164. Wang P.Y., et al. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 2005, 307:1472-1476.
165. Wang W.X., et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 2008, 28:1213-1223.
166. Wang Z., et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 2008, 40:897-903.
167. Westbrook T.F., et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008, 452:370-374.
168. Wong P.T., et al. Ornithine aminotransferase in Huntington's disease. Brain Res. 1982, 231:466-471.
169. Wu J., Xie X. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol. 2006, 7:R85.
170. Yoo A.S., et al. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009, 460:642-646.
171. Zeron M.M., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002, 33:849-860.
172. Zeron M.M., et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell Neurosci. 2004, 25:469-479.
173. Zheng D., et al. Profiling RE1/REST-mediated histone modifications in the human genome. Genome Biol. 2009, 10:R9.
174. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.
175. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
176. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
177. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
178. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
179. Zuccato C., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 2007, 27:6972-6983.